PrEP, or pre-exposure prophylaxis, was first approved by the FDA in 2012 to prevent people exposed to HIV from becoming ...

Apretude, Descovy, Truvada, and a generic version of Truvada—often referred to as PrEP—are approved for men at high risk of acquiring HIV. By Lisa L. Gill Updated by Justin Krajeski About ...

Cost may be an important factor in which version of oral PrEP you decide to take, especially if your healthcare system or insurance does not reimburse for the medication. The patent for branded ...

Gilead is looking towards approval of lenacapavir as HIV PrEP after reporting near-perfect efficacy in the PURPOSE-1 and ...

The Scottish Medicines Consortium has approved the use of Gilead’s Truvada for use in preventing new HIV infections, so called pre-exposure prophylaxis (PrEP). The decision has been hailed as a ...

Gilead Sciences has filed Descovy, its successor to HIV pre-exposure prophylaxis (PrEP) therapy Truvada, in the US, spending a priority review voucher (PRV) to set up a verdict within six months.

Historically, as mentioned, PrEP has been used to treat cisgender gay men, especially in light of the HIV crisis of the 1980s ...

Truvada (emtricitabine/tenofovir disoproxil fumarate) is prescribed to treat and help prevent HIV-1. This drug can interact with other medications. For example, Truvada can interact with certain ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced additional data from its pivotal Phase 3 PURPOSE 2 trial (NCT04925752) ...

While the daily PrEP pills Truvada and Descovy (both from Gilead) are around 99% effective when taken consistently, additional options are still needed. Some people have trouble remembering to take a ...

Two large studies were conducted to see if Apretude is safe and effective as a PrEP regimen in people at risk of getting HIV. In both studies, Apretude was compared to Truvada, an HIV PrEP ...

The trial pitted PrEP lenacapavir against standard-of-care once-daily Truvada (emtricitabine + tenofovir disoproxil fumarate). New safety data from the trial indicated that lenacapavir was ...